Yükleniyor... / Loading...
This study evaluates the effect of supplementation with the gut bacterium Akkermansia muciniphila on weight maintenance. Participants with a body mass index of 28-40 whose weight had been stable for at least 3 months were included, with some receiving placebo instead of the supplement. The study had no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * BMI ≥ 28 kg/m2 \< 40 kg/m2 * Weight stable for at least 3 months (± 2 kg). Exclusion Criteria: * Type 2 diabetes mellitus (fasting plasma glucose ≥ 7.0 mmol/L) * Gastroenterological diseases * Surgery on the gastrointestinal tract (ex.Bariatric surgery) * Cardiovascular diseases, cancer, liver or kidney malfunction, a disease with a life expectancy of \< 5 years; * Alcohol (\>15 standard drinks per week) or drug abuse * Excessive nicotine use is defined as \>20 cigarettes per day; * Use of prebiotics or probiotics 3 months prior to the start of the study; * Intensive exercise training, \> 3 hours a week; * Use of any medication influencing glucose or fat metabolism (ex. lipid-lowering-drugs e.g. PPAR γ (peroxisome proliferator-activated receptors) or PPARα (fibrates) agonists), glucose-lowering agents (including all sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinediones, repaglinide, nateglinide, and insulin), inflammation (e.g. anti-inflammatory or immunosuppressive drugs) and anti-oxidants); * Regular use of laxatives * Use of antibiotics in the last 3 months * Vegan * Lactose intolerance * Pregnancy or lactation * Concomitant participation in another study